At SIU Medicine, our researchers perform clinical trials and research studies with the aim of translating findings into new, more effective treatments.
The purpose of this clinical trial is to assess the effectiveness of Epetraborole, taken once daily, in patient populations with treatment-refractory MAC lung disease.
Eligible patients include those who currently have a positive MAC sputum culture despite receiving a combination regimen of at least 2 antimycobacterial agents administered for at least 6 months.
The purpose of this study is to assess the effect of BMS-986446 vs placebo on delay of cognitive memory and functional decline in participants (age 50-80) with early Alzheimer's Disease.
The purpose of this study is to learn more about the safety, effectiveness and tolerability of the study drug called Benfotiamine, to determine whether it delays or slows the progression of the symptoms of early Alzheimer’s disease.
This research will be conducted by the SIU Memory and Aging Network (MAN), which comprises 38 sites that evaluate and treat patients with dementia throughout non-metropolitan Illinois. AD patients and their caregivers who are living in private homes will be recruited. Primary outcome measures will be the ratings of the caregiver’s physical status (grip strength, walking speed, and score on the Timed Up-and-Go Test11 and the rating of the caregiver’s chronic medical illness burden using the Cumulative Illness Rating Scale (Geriatric).12,13 The patient and caregiver dyad is required.
The purpose of this clinical trial is to assess the effectiveness of ARIKAYCE, inhaled once daily, in patient populations with mild and untreated MAC lung infection.
Eligible patients include those who currently have a positive MAC sputum culture and have not received treatment for their infection.
